

1 An improved genome editing system for Sphingomonadaceae

2 Inmaculada García-Romero^{1,†}, Rubén de Dios^{2,†,*} and Francisca Reyes-Ramírez^{1,*}

3 1. Departamento de Biología Molecular e Ingeniería Bioquímica, Centro Andaluz de Biología
4 del Desarrollo, Universidad Pablo de Olavide/Consejo Superior de Investigaciones
5 Científicas/Junta de Andalucía, 41013 Sevilla, Spain.

6 2. Division of Biosciences, Department of Life Sciences, Centre of Inflammation Research
7 and Translational Medicine, College of Health, Medicine and Life Sciences, Brunel University
8 London, Uxbridge, UK.

9

10 †: These authors contributed equally to this work.

11 *: Authors to whom correspondence should be addressed: R. de Dios
12 (ruben.dediosbarranco@brunel.ac.uk) and F. Reyes-Ramírez (freynam@upo.es).

13

14 Abstract

15 The sphingomonads encompass a diverse group of bacteria within the Sphingomonadaceae
16 family, with the presence of sphingolipids on their cell surface instead of lipopolysaccharide
17 as their main common feature. They are particularly interesting for bioremediation purposes
18 due to their capability to degrade or metabolise a variety of recalcitrant organic pollutants.
19 However, the research and development of their full bioremediation potential has been
20 hampered because of the limited number of tools available to investigate and modify their
21 genome. Here, we present a markerless genome editing method for *Sphingopyxis granuli*,
22 which can be further optimised for other sphingomonads. This procedure is based on a
23 double recombination triggered by a DNA double strand break in the chromosome. The
24 strength of this protocol lies in forcing the second recombination rather than favouring it by
25 pressing a counterselection marker, thus avoiding laborious re-streaking or passaging
26 screenings. Additionally, we introduce a modification with respect to the original protocol to
27 increase the efficiency of the screening after the first recombination event. We show this
28 procedure step by step and compare our modified method with respect to the original one by
29 deleting *ecfG2*, the master regulator of the general stress response in *S. granuli*. This adds
30 onto the genetic tool repertoire that can be applied to sphingomonads and stands as an
31 efficient option for fast genome editing of this bacterial group.

32

33 **Keywords:** sphingomonads, Sphingomonadaceae, genome editing, genetic tools, mutation,
34 bioremediation

35

36 **Introduction**

37 Sphingomonads is a bacterial group encompassing the genera *Sphingobium*, *Sphingopyxis*,
38 *Novosphingobium*, and *Sphingomonas*, which classified within the Sphingomonadaceae
39 family [1, 2]. The members of the Sphingomonadaceae family are Gram-negative
40 alphaproteobacteria of various sizes that do not form spores. They can be motile or non-
41 motile, and when they are, they often have a polar flagellum. The colonies they form exhibit
42 yellow or orange tones due to the presence of carotenoids and contain sphingolipids
43 (glycosphingolipids) in their cell envelopes instead of lipopolysaccharides (reviewed in [3]).
44 Sphingomonads are widely distributed in nature, as they inhabit multiple terrestrial and
45 aquatic environments, and have been isolated from plant roots, clinical samples, and other
46 sources [4]. Some of them have been also found to be endophytic [5, 6] and assist in
47 phytoremediation processes (reviewed in [7]) and it has been described a facultative
48 anaerobe, *Sphingopyxis granuli* strain TFA, which is able to growth in anaerobic conditions
49 in the presence of nitrate [8].

50 Among the Sphingomonadaceae family, sphingomonads are well known for their capability
51 to degrade recalcitrant compounds, including aromatic hydrocarbons. Examples of
52 sphingomonads with this ability are *Sphingopyxis granuli*, which is capable of used tetralin
53 as the sole carbon and energy source [9]; *Sphingomonas aromaticivorans* F199, which
54 degrades biphenyl, naphthalene, m-xylene and p-cresol [10]; *Sphingomonas wittichii* RW1,
55 which catabolises dibenzo-p-dioxin [11] or *Sphingobium chlorophenolicum* L-1, which
56 catabolises pentachlorophenol [12]. Some members of this group are even able to
57 metabolise pharmaceutical agents, such as *Sphingomonas sp.* MPO218, which utilises
58 ibuprofen as carbon source [13]. Additionally, *Sphingopyxis macrogoltabida* NBRC 15033
59 and *Sphingopyxis sp.* PVA3 are able to degrade synthetic polymers such as polyethylene
60 glycol (PEG) [14] and polyvinyl alcohol (PVA) [15], respectively, employed in the production
61 of plastic items, adhesives or packaging films [16]. Due to the ability to degrade xenobiotic
62 compounds, this group of bacteria has gained a special interest in the bioremediation field.
63 However, as non-model microorganisms, they have been lagging behind in the development
64 of efficient genetic tools and genome editing technologies. The further development of these
65 tools is essential for fully understanding the biodegradation pathways and physiology of this
66 group of bacteria and to maximise their bioremediation potential.

67 In this regard, basic genetic tools have been developed for mutational analyses and targeted
68 mutagenesis in Sphingomonadaceae, including gene disruption and replacement
69 strategies. However, these methods may cause polar effects on the genes located
70 downstream in an operon. This hindrance led to the development of markerless gene
71 deletion strategies based on a double recombination involving successive selection-
72 counterselection rounds. In a first round, a plasmid harboring the upstream and downstream
73 homologous regions of the target gene is transferred to the strain of interest and the first
74 recombination into the chromosome is selected typically using an antibiotic resistance
75 marker. In addition to this selection marker, plasmids used for markerless gene deletion
76 procedures include a counterselection marker that may confer sensitivity to specific
77 compounds, depending on the marker. By growing the cointegrate strain in the presence of
78 this compound, only cells undergoing a second recombination and losing the plasmid
79 backbone will be able to grow. A classic example of a counterselection marker is *sacB*, which
80 confers sensitivity to sucrose and has been applied to different members of the
81 Sphingomonadaceae [17-23]. The *sacB* marker confers sensitivity to sucrose, thus growing
82 the cointegrate clones in the presence of this disaccharide after a first recombination would
83 favour a second recombination. This second recombination event would lead either to the
84 reconstitution of the wild-type genomic configuration or to the stable introduction of the
85 aimed genome modification. However, the highly frequent emergence of spontaneous
86 sucrose-resistant mutants and the need of multiple rounds of sub-culturing in the presence
87 of sucrose make this system tedious and poorly reproducible [24]. Kaczmarczyk *et al.* (2012)
88 [24] developed a similar strategy with a better reproducibility taking advantage of the natural
89 streptomycin resistance of sphingomonads, which has been extensively used since its
90 publication [25-40]. In this case, they engineered an artificial allele of *rpsL*, termed *rpsL1*,
91 that confers sensitivity to streptomycin and can be used as a counterselection marker.
92 Despite the unquestionable technical improvement tested for a range of sphingomonads, the
93 streptomycin sensitivity produced by *rpsL1* varied across species, which may again need
94 further passaging or re-streaking to achieve the second recombination.

95 To accelerate the double-recombination procedure, Martínez-García and de Lorenzo (2011)
96 [41] developed a method for genome editing in *Pseudomonas putida*, subsequently modified
97 by Wirth *et al.* (2020) [42], in which the second recombination is triggered by a DNA double-
98 strand break. This addition would avoid the need of a counterselection marker, by-passing
99 the re-streaking/passaging steps and hence shortening the protocol. In this method, the
100 upstream and downstream homologous regions of the target gene are cloned in a non-
101 replicative plasmid flanked by two *SceI* restriction sites termed pEMG. After the introduction
102 of this vector, first recombination event, a second vector carrying the *SceI* coding gene under

103 an inducible promoter, termed pSW-I, is transferred into the cointegrate strain. The
104 expression of *sceI* produces a double-strand break in the cognate restriction sites that is
105 eventually repaired by homologous recombination, resolving the cointegrate and either
106 producing the deletion of the target gene or a reversal to the wild-type genotype. The
107 strength of this method lies in the need to forcefully repair the double-strand break by
108 recombination, regardless of a counterselection, for which the strain of interest may develop
109 secondary adaptations or resistance mutations. Thanks to its high efficiency and versatility,
110 this genome editing strategy has been extensively applied for single gene deletions, as well
111 as for the removal whole gene clusters and insertion of epitopes in various species [43-48].
112 Furthermore, it has even been adapted to other bacteria that have remained reluctant to
113 gene manipulation, including multidrug-resistant *Acinetobacter baumannii*, in which it has
114 been used to edit the chromosome as well as native plasmids [49].

115

116 In this work, we describe the optimisation of the *SceI*-based genome editing method to
117 *Sphingopyxis granuli* TFA, supporting its further applicability to the Sphingomonadaceae
118 family. Furthermore, we implement this strategy with additions from Kaczmarczyk *et al.*
119 (2012) to improve the detection of single-recombinant clones. The improvement of this
120 method with respect to traditionally-used counterselection-based procedures lies in forcing a
121 second recombination rather than just favouring it. We do this by deleting *ecfG2*, a well-
122 known regulator of the alphaproteobacterial general stress response (GSR) and showing the
123 effect of the deletion on the GSR activation with respect to the wild type TFA. We also
124 provided the guidelines of this procedure in a step-by-step comprehensive protocol.

125 **Protocol optimization: methods and results**

126 Plasmid construction

127 The original plasmids to perform the *SceI*-based genome editing strategy, pEMG (kanamycin
128 resistance (Km^R)) and pSW-I (ampicillin resistance (Ap^R)) were kindly provided by Prof. V. de
129 Lorenzo (CNB, Madrid). Plasmids pMPO1409 (Km^R, carrying upstream and downstream
130 homologous regions to delete *ecfG2* in *S. granuli* TFA) pMPO1408 (Ap^R, carrying a
131 *ecfG2::lacZ* gene fusion) and pMPO1412 (Km^RStr^S (streptomycin sensitivity)) were
132 previously constructed as described in de Dios *et al.* (2020) [50] and González-Flores *et al.*
133 (2019) [51], respectively. For the purpose of comparing the original protocol (using pEMG-
134 derivative plasmids) and the subsequent improvements using pMPO1412-derivative
135 plasmids (introducing the *rpsL1* counterselection marker in pEMG), we constructed
136 pMPO1162, a pMPO1412-derivative carrying the above mentioned *ecfG2* homologous
137 regions. This construction was performed by digesting pMPO1409 with *SacI* and *XbaI* (New

138 England Biolabs), purifying a 2 kb fragment containing the *ecfG2* homologous regions using
139 the GFX (GE Healthcare Life Sciences) DNA purification kit, and ligating it into pMPO1412
140 digested with the same enzymes using T4 DNA ligase (New England Biolabs). Enzymatic
141 reactions and purification procedures were performed as per the manufacturer's instructions.
142 Chemically competent *Escherichia coli* DH5 α λ pir were transformed with ligation mixtures
143 via heat-shock transformation.

144 The use of *rpsL1* counterselection improves the screening of cointegrate candidates

145 Traditionally, kanamycin has been used as a selection marker in sphingomonads in general
146 and in *S. granuli* in particular. However, when selecting single-recombination events, the
147 recombination frequency is similar to that of spontaneous kanamycin resistant mutants
148 (Figure 1). Due to this, the distinction of cointegrates carrying pEMG derivatives with the
149 upstream and downstream regions of the target gene required tedious screening by PCR. In
150 our efforts to make this step more efficient, we cloned the *rpsL1* counterselection marker in
151 pEMG, obtaining pMPO1412 in previous work [51]. In order to compare both approaches,
152 we attempted to delete *ecfG2* using backbone plasmids with and without carrying the *rpsL1*
153 allele in parallel. To do this, *S. granuli* TFA was electrotransformed with 200 ng of
154 pMPO1409 or pMPO1162, or an equivalent amount of bi-distilled water as a control. All
155 transformations were performed in biological triplicate and serial dilutions were plated on
156 MML agar supplemented with 20 mg/L kanamycin (plain MML agar for viable cell counting).
157 As a result, we confirmed that the spontaneous emergence of kanamycin resistant mutants
158 in the control transformations was not significantly different from that obtained in the
159 transformations with pMPO1409 and pMPO1162.

160 To identify the cointegrate clones, we performed a screening with all the resulting kanamycin
161 resistant colonies by streaking them on MML agar plates supplemented with either 20 mg/L
162 kanamycin alone or with 20 mg/L kanamycin and 200 mg/L streptomycin (four-fold the
163 concentration of streptomycin we routinely use to select the wild-type TFA strain), which
164 would negatively impact the growth of the clones carrying the *rpsL1* marker. Then, the agar
165 plates were incubated at 30 °C for just 16 h (all the streaks would look equally grown if
166 incubated beyond 18-20 hours). As expected, colonies taken from control plates and those
167 transformed with pMPO1409 grew at similar rates in media supplemented with kanamycin
168 only or with kanamycin and streptomycin (Figure 2A,B). However, plates streaked with
169 colonies obtained by transforming TFA with pMPO1162, harbouring *rpsL1*, showed multiple
170 clones that grew visibly slower in the presence of kanamycin and streptomycin compared to
171 those grown in the presence of kanamycin only (Figure 2C).

172 To test the efficacy of this counterselection as an improvement to the screening process, we
173 performed an additional PCR screening using primers that annealed within the kanamycin
174 resistance marker harboured in pMPO1409 and pMPO1162, yielding an amplicon of
175 approximately 700 bp (KmFw: GATTGAACAAGATGGATTGC; KmRev:
176 CGTCAAGAAGGCGATAGAAGG). To do this screening, we randomly selected 10 clones
177 from each of the 3 pools obtained by transforming with pMPO1409, as well as 5 targeted
178 clones transformed with pMPO1162 that grew slower in the presence of kanamycin and
179 streptomycin. As shown in Figure 3, only 7 out of 30 clones transformed with pMPO1409
180 yielded a PCR product, indicative of having undergone the first recombination event.
181 However, all 5 clones tested from the transformation with pMPO1162 yielded a PCR product.
182 This conclusively shows how using the *rpsL1* counterselection as an indication of the first
183 recombination event reduces the number of clones to test and
184 yields a more targeted and efficient screening.

185 The transformation with pSW-I triggers the second recombination

186 At this point, the plasmid carrying the upstream and downstream homologous regions of the
187 target gene (*ecfG2* in this case) flanked by the *SceI* restriction sites would be inserted in the
188 TFA chromosome by a single recombination event. The next step consists in forcing the
189 second recombination that would lead to the *ecfG2* deletion. To do this, a replicative plasmid
190 carrying the *sceI* gene needs to be transferred into the selected cointegrate clone. To
191 perform this step, we selected clones 3, 4 and 5 as labelled in Figure 2C, prepared
192 electrocompetent cells of each of them and transformed them with 200 ng of pSW-I in
193 parallel to the respective three controls with an equivalent amount of water. Selection was
194 carried out on MML agar supplemented with ampicillin 5 mg/L. In this case, the
195 transformation frequency with pSW-I was significantly higher than the emergence of
196 spontaneous ampicillin resistant clones (Figure 4).

197 In the original *P. putida* protocol, both the pEMG derivative construct and the pSW-I plasmid
198 are simultaneously selected prior to inducing the *sceI* expression. However, during our first
199 attempts to use this procedure, we observed a very poor growth when selecting both genetic
200 elements at the same time. A possible explanation would be that the presence of both the
201 cointegrate and pSW-I simultaneously has a strong fitness cost due to the leaky expression
202 of *sceI*. This would continuously produce double-strand breaks in the *SceI* target site
203 introduced in the chromosome with the first recombination step. For this reason, rather than
204 selecting the presence of both elements at the same time as in the original protocol [41], we
205 selected only the presence of pSW-I. In addition to this, the original protocol requires the
206 induction of the *sceI* expression by adding 3-methylbenzoate. This was further optimised by

207 Wirth *et al.* (2020) [42] by doing the pSW-I selection and *sceI* induction in a single step.
208 However, during the optimisation of this protocol for the use on *S. granuli* TFA, we noticed
209 that the leaky expression of *sceI* alone was enough to trigger the DNA double-strand break.
210 This has also been observed for other bacteria, for which the addition of 3-methylbenzotae is
211 even deleterious for the growth [49].

212 For these reasons, we directly screened the ampicillin resistant, kanamycin sensitive clones
213 obtained after the transformation with pSW-I (50 clones per transformation) by streaking
214 them on MML agar plates supplemented with either 20 mg/L kanamycin, 5 mg/L ampicillin or
215 50 mg/L streptomycin (Supplementary Figure S1). After this, we obtained that, for each of
216 the three independent pSW-I transformations, 48%, 62% and 30% of the clones were
217 kanamycin sensitive, indicating that they had undergone a second recombination event
218 during the selection process.

219 To assess if the second recombination had led to the deletion of *ecfG2* or if the clone had
220 reverted to the wild type genotype, we screened 10 clones of each transformation by PCR.
221 We used primers Seq_ecfG2_Fw2 (ACCGATTTTGCCCATGGCTTC) and Seq_ecfG2_Rv
222 (CGAACGGAAACAGAGGTGATC), which would yield a product of approximately 1 kb in the
223 case of the wild type configuration or approximately 0.5 kb in the case of the *ecfG2* deletion.
224 As a result, 21 out of 30 total clones had suffered the deletion of *ecfG2* (Figure 5).

225 As a final step, pSW-I have to be cured from the deletion mutant. To do this, we inoculated
226 one positive clone from each pSW-I transformation in MML broth in the absence of
227 ampicillin. After two passages, cells were serially diluted and plated on MML agar
228 supplemented with 50 mg/L streptomycin. To conclusively assess the loss of both
229 pMPO1162 and pSW-I, 50 colonies obtained from plating each individual clone were
230 streaked on MML agar supplemented with either 20 mg/L kanamycin, 5 mg/L ampicillin or 50
231 mg/L streptomycin. As a result, none of the clones grew in the presence of kanamycin or
232 ampicillin, but all grew in the presence of streptomycin (Supplementary Figure S2), which
233 indicated the curation of all genetic devices used in this deletion strategy. A scheme
234 summarising the recombinations and genetic rearrangements undergone during this
235 procedure is shown in Figure 6.

236 The deletion of *ecfG2* abolishes the expression of *nepR2*

237 EcfG2 is an extracytoplasmic function sigma factor that acts as the main regulator of the
238 GSR in *S. granuli* TFA [49, 50]. Although *ecfG2* is essential under stressing conditions, a
239 mutant in this gene shows a similar fitness compared to the wild type TFA in the absence of
240 stress. Among its target genes, *nepR2* encodes an anti-sigma factor that exerts a negative
241 feedback loop on the activation of the GSR [49]. To show the phenotype of the new

242 constructed $\Delta ecfG2$ mutant, we transformed the $\Delta ecfG2$ mutant along with the wild type TFA
243 with pMPO1408, an integrative vector carrying a *nepR2::lacZ* gene fusion. Thus, EcfG2-
244 mediated activation of the GSR, and thus *nepR2*, would lead to the production of the β -
245 galactosidase enzyme that breaks down X-gal (5-bromo-4-chloro-3-indolyl- β -D-
246 galactopyranoside) into a blue precipitate. To visualize this, we streaked both the wild type
247 TFA and the $\Delta ecfG2$ deletion mutant, both carrying the *nepR2::lacZ* fusion, on a MML agar
248 plate supplemented with 25 mg/L X-gal and incubated it at 30 °C for 5 days. As a result, we
249 observed that the wild type TFA yielded a blue colour, whereas the $\Delta ecfG2$ deletion mutant
250 would not produce this precipitate (Figure 7). This is coherent with previous studies, showing
251 that a mutant in *ecfG2* has a null ability to activate the GSR, including the expression of
252 *nepR2* [50].

253

254 Discussion

255 In this work, we describe an efficient genome editing procedure with potential applicability in
256 sphingomonads, using *S. granuli* as a model. Traditionally, mutational studies involving this
257 group of bacteria have been developed via marked mutation or counterselection-mediated
258 double recombination. The *sacB* gene has been the most frequently used counterselection
259 marker, although alternative counterselection markers have been described, including *pheS*,
260 which provides sensitivity to p-chlorophenylalanine [52]. However, there are representatives
261 of this group that are naturally sensitive to this compound [24], making it not generally
262 applicable to these procedures. Even in the case of *sacB*, previous reports have shown that
263 its presence in the absence of selection can generate a certain toxicity that leads to
264 accumulating mutations that inactivate it [53], thus rendering it ineffective for
265 counterselection. This has also been observed when applying this strategy in members of
266 the Sphingomonadaceae [24]. The optimised protocol we present here takes advantage of
267 the natural streptomycin resistance of sphingomonads to indicate a successful first
268 recombination, combined with a DNA double-strand break induction that efficiently triggers a
269 second recombination. This strategy offers a fast-track procedure compared to the
270 previously mentioned double recombination-based genome editing protocols.

271 Although we present an optimisation of the procedure to *S. granuli*, the protocol is further
272 amenable to different modifications that may tailor it to the specificities of other
273 sphingomonads. For example, we use electrotransformation as a means to introduce
274 plasmids in *S. granuli*. However, both pMPO1412 (and the parental pEMG) and pSW-I are
275 mobilisable via biparental or triparental mating, which may be an alternative for
276 sphingomonads in which electrotransformation is not applicable. Furthermore, the selection

277 markers in the pMPO1412 (and pEMG) and pSW-I can be exchanged according to the
278 resistance profile of other sphingomonads. In this regard, several versions of pEMG and
279 pSW-I derivatives with different selection markers are available through the Standard
280 European Vector Architecture platform [54]. Another aspect that may be attuned to the
281 requirements of other sphingomonads is the Sce-I expression induction step. In the case of
282 *S. granuli*, the leaky expression of Sce-I, which is inducible by 3-methylbenzoate under the
283 XylS-*Pm* system [41], was enough to trigger the second recombination. However, this
284 expression system may behave differently in other species, and the addition of the inducer in
285 the selection plates after introducing pSW-I may be required [42].

286 All in all, we describe a powerful tool for genome editing in *S. granuli* that can be further
287 tailored to the requirements of other sphingomonad models.

288

289 **Summary step-by-step protocol**

290 Here, we describe a step-wise protocol to perform this genome editing strategy on *S. granuli*,
291 which can be used as a base for optimisation to other sphingomonad species and laboratory
292 methods (e.g. culture media, incubation times, selection/screening procedures). The protocol
293 is described once the pMPO1412-derivative vector has been constructed and purified.

294 First recombination event

295 *Day 1: inoculation*

- 296 • Inoculate 3 ml of MML broth with wild type *S. granuli* TFA. Incubate at 30 °C, 180 rpm
297 to saturation (typically 24 h). MML broth recipe is provided as supplementary
298 material.

299 *Day 2: electrotransformation with the pMPO1412-derivative plasmid*

- 300 • Prepare *S. granuli* electrocompetent cells (our in-house protocol has been provided
301 as supplementary material). Alternatively, the pMPO1412 derivative can be
302 introduced in the target strain by triparental mating.
- 303 • Electrotransform with 200 ng of the purified pMPO1412-derivative plasmid using an
304 electroporator.
- 305 • Reconstitute the electroporated cell mixture with 1 ml of ice-chilled MML broth
306 supplemented with 0.5 M sorbitol or 10% glycerol. Incubate at 30 °C, 180 rpm for 1.5
307 h.

- 308 • Perform serial dilution and plating on MML agar plates supplemented with kanamycin
309 20 mg/L for selection. Incubate the plates at 30 °C for 4-5 days.

310 *Day 3: first recombination screening*

- 311 • Perform dual streaking of 50-100 clones on two MML agar plates: one supplemented
312 with kanamycin 20 mg/L and other one supplemented with kanamycin 20 mg/L and
313 streptomycin 200 mg/L. Incubate the plates at 30 °C for approximately 16 h.

314 *Day 4: first recombination screening results*

- 315 • By direct visualization, select the clones that grew well on MML agar with kanamycin
316 only but grew slower on MML agar with kanamycin and streptomycin.
- 317 • To validate these recombinant clones, perform a colony PCR using specific primers
318 to the plasmid introduced (we typically use primers annealing in the kanamycin
319 resistance marker).
- 320 • Inoculate one of the validated cointegrate clones in 3 ml of MML broth to continue on
321 to the second recombination event.

322 *Day 5: electrotransformation with pSW-I*

- 323 • Prepare electrocompetent cells of the cointegrate clone.
- 324 • Electrotransform the cointegrate clone with 200 ng of purified pSW-I.
- 325 • Reconstitute the electroporated cell mixture with 1 ml of ice-chilled MML broth
326 supplemented with 0.5 M sorbitol or 10% glycerol. Incubate at 30 °C, 180 rpm for 1.5
327 h.
- 328 • Perform serial dilution and plating on MML agar plates supplemented with ampicillin
329 5 mg/L for selection. Incubate the plates at 30 °C for 4-5 days.

330 *Day 6: second recombination screening*

- 331 • Perform multiple streaking of 50 clones on three MML agar plates: one supplemented
332 with kanamycin 20 mg/L, other one supplemented with ampicillin 5 mg/L and one last
333 plate supplemented with streptomycin 50 mg/L. Incubate the plates at 30 °C for 24 h.

334 *Day 7: second recombination screening results and mutation screening*

- 335 • By direct visualization, select the clones that grew on MML agar with ampicillin only
336 but did not grow on MML agar with kanamycin and ampicillin.

337 • To validate these recombinant clones and identify those that underwent the genetic
338 modification, perform a colony PCR using specific primers flanking the gene targeted
339 for deletion in order to distinguish PCR products of different sizes between the wild
340 type and the mutant strain. Other modifications may require alternative validation
341 approaches (e.g. other primer combinations for DNA insertions, Sanger sequencing
342 for point mutation)

343 • Inoculate one of the validated mutant clones from those streaked on plain MML agar
344 in 3 ml of MML broth start the curation on pSW-I Incubate at 30 °C, 180 rpm for 24 h.

345 *Day 8: pSW-I curation*

346 • Perform a passage of the mutant strain by doing a 1/500 dilution in fresh MML broth.
347 Incubate at 30 °C, 180 rpm for 24 h.

348 *Day 9: pSW-I curation*

349 • Repeat passaging as in Day 8.

350 *Day 10: pSW-I curation*

351 • Streak on MML agar to obtain isolated colonies. Incubate at 30 °C for 24 h.

352 *Day 11: validation of pSW-I-cured mutant clones*

353 • Perform dual streaking of 50 clones on two MML agar plates: one supplemented with
354 ampicillin 5 mg/L and a plain MML agar. Incubate the plates at 30 °C for 24 h.

355 *Day 12: selection of pSW-I-cured clones*

356 • By direct visualization, select the clones that grew on plain MML agar but did not
357 grow on MML agar supplemented with ampicillin and neither with kanamycin. Re-
358 streak on plain MML agar to obtain isolated colonies. Use these isolated colonies for
359 cryoconservation of the newly generated mutant strain.

360

361 **Data summary**

362 All data and protocols used or generated through this work have been provided within this
363 article or in the associates supplementary files.

364

365 **Acknowledgements**

366 We would like to thank Prof Eduardo Santero, Prof Fernando Govantes and Dr Elena Rivas-
367 Marín, as well as the rest of the member of the Division of Microbiology of the University
368 Pablo de Olavide (Seville, Spain), for their advice and suggestions during the optimisation of
369 this method, and Dr Guadalupe Martín-Cabello for the technical support.

370 **Funding**

371 This work has been supported by the grant PID2021-125491NB-I00 funded by
372 MICIU/AEI/10.13039/501100011033 (Ministerio de Ciencia, Innovación y Universidades /
373 Agencia Estatal de Investigación) and FEDER (UE) to FR-R. IGR is supported by a
374 postdoctoral contract (PAIDI 2020, POSTDOC_21_00064) funded by the Andalusian
375 Government (Junta de Andalucía). RD is supported by a Biotechnology and Biological
376 Sciences Research Council New Investigator Award (BB/V007823/1) awarded to Dr Ronan
377 McCarthy.

378 **Author contribution**

379 IGR designed and performed experimental work and drafted and edited the manuscript. RD
380 originally conceived this work, designed and performed experimental work and drafted and
381 edited the manuscript. FRR designed and supervised the work and edited the manuscript.


382

383 **Conflict of interest**

384 RD is an Editor for Access Microbiology.

385


386 **Figures and figure legends**



387


388 **Figure 1.** Logarithmic representation of *S. granuli* transformation frequency when
 389 transforming with pMPO1409 (-*rpsL1*) and pMPO1162 (+*rpsL1*) compared to a control
 390 (spontaneous). 200 ng of the respective plasmid (an equivalent volume of water in the case
 391 of the control) were used in each case. Each transformation was repeated with three
 392 independently prepared aliquot of electrocompetent *S. granuli* TFA cells. Individualised
 393 colony counts for each repeat and frequency calculations are shown in Supplementary Table
 394 S1. One-way ANOVA analysis was performed between the different samples; n.s.: non-
 395 significant.

396



397 **Figure 2.** Streaks of clones obtained from the control electroporation (A), or
 398 electrotransformations with pMPO1409 (*-rpsL1*) (B) or pMPO1162 (*+rpsL1*) (C). The red-


399 labelled streaks do not grow or grow slowly with Km 20 mg/L plus Str 200 mg/L when
400 compared to the same streaks growing with only Km 20 mg/L (labelled in green). Results for
401 the previously mentioned three independent electrotransformation replicates are shown, as
402 well as controls in which the electroporation was performed with an equivalent volume of




403 water.

404

405 **Figure 3.** Agarose gel electrophoresis (0.8%) of PCR products from different clones after
406 electrotransforming with pMPO1409 (*-rpsL1*) or pMPO1162 (*+rpsL1*), using the primers
407 KmFw (GATTGAACAAGATGGATTGC) and KmRev (CGTCAAGAAGGCGATAGAAGG). The
408 plasmids pMPO1409 and pMPO1162 were used as positive (+ve) controls, respectively, and
409 no DNA was added in negative (-ve) control.




410 **Figure 4.** Logarithmic representation of transformation frequency when introducing pSW-I
 411 into each independent cointegrate clone compared to the respective negative controls. 200
 412 ng of plasmid were used in each case, and an equivalent amount of water was used for the
 413 negative controls. Individualised colony counts for each repeat and frequency calculations
 414 are shown in Supplementary Table S2. T-Student analysis was performed between the
 415 different samples. * = p<0.05.



416 **Figure 5.** Agarose gel electrophoresis (0.8%) of PCR product from different clones of
 417 second recombination event, using the oligos Seq_ecfG2_Fw2
 418 (ACCGATTTTGCCCATGGCTTC) and Seq_ecfG2_Rv (CGAACGGAAACAGAGGTGATC).
 419 The plasmid used in the electroporation were pSW-I. Genomic DNA from wild type TFA

420 strain was used as positive (+ve) control and no DNA was added in negative (-ve) control.



421 Wild type fragment is ~1000 bp and the deletion of *ecfG2* is shown as a ~500 bp fragment.

422 **Figure 6.** Schematic representation of the genetic rearrangements and recombinations
423 occurring during this genome editing procedure for a generic target gene (*ecfG2* in the
424 example developed in this work), as well as the two possible outcomes: a reconstitution of
425 the wild-type genotype or the aimed genome modification.

426

427


428

429

430

431

432



433

434 **Figure 7.** Expression of *nepR2::lacZ* fusion in the mutant Δ *ecfG2* compared to the wild type
 435 (WT) TFA strain. EcfG2 is essential for activating the expression of *nepR2* (de Dios *et al.*,
 436 2020). Thus, the *nepR2::lacZ* fusion (born in pMPO1408) in the Δ *ecfG2* background does
 437 not yield a blue colour in the presence of X-gal. Both strains were streaked on MML agar
 438 plates supplemented with X-gal 25 mg/L and were incubated at 30 °C for 5 days.

439

440 **References**

- 441 1. Takeuchi, M., K. Hamana, and A. Hiraishi, *Proposal of the genus Sphingomonas sensu stricto*
 442 *and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of*
 443 *phylogenetic and chemotaxonomic analyses.* Int J Syst Evol Microbiol, 2001. **51**(Pt 4): p.
 444 1405-17.
- 445 2. Kosako, Y., et al., *Proposal of Sphingomonadaceae fam. nov., consisting of Sphingomonas*
 446 *Yabuuchi et al. 1990, Erythrobacter Shiba and Shimidu 1982, Erythromicrobium Yurkov et al.*
 447 *1994, Porphyrobacter Fuerst et al. 1993, Zymomonas Kluyver and van Niel 1936, and*
 448 *Sandaracinobacter Yurkov et al. 1997, with the type genus Sphingomonas Yabuuchi et al.*
 449 *1990.* Microbiol Immunol, 2000. **44**(7): p. 563-75.
- 450 3. Glaeser, S.P. and P. Kämpfer, *The Family Sphingomonadaceae.*, in *The Prokaryotes*, E.
 451 Rosenberg, et al., Editors. 2014, Springer: Berlin, Heidelberg. p. 641-707.
- 452 4. Balkwill, D.L., J.K. Fredrickson, and M.F. Romine, *Sphingomonas and Related Genera*, in *The*
 453 *Prokaryotes*, M. Dworkin, et al., Editors. 2006, Springer: New York. p. 605-629.

- 454 5. Battu, L., et al., *Assembly of genomic reads of elite indica rice cultivar onto 2101 reference*
455 *bacterial genomes for identification of co-sequenced endophytic bacteria*. Data Brief, 2017.
456 **12**: p. 305-312.
- 457 6. Battu, L., et al., *Genome inside genome: NGS based identification and assembly of endophytic*
458 *Sphingopyxis granuli and Pseudomonas aeruginosa genomes from rice genomic reads*.
459 Genomics, 2017. **109**(3-4): p. 141-146.
- 460 7. Gatheru Waigi, M., K. Sun, and Y. Gao, *Sphingomonads in Microbe-Assisted*
461 *Phytoremediation: Tackling Soil Pollution*. Trends Biotechnol, 2017. **35**(9): p. 883-899.
- 462 8. García-Romero, I., et al., *Genomic analysis of the nitrate-respiring Sphingopyxis granuli*
463 *(formerly Sphingomonas macrogoltabida) strain TFA*. BMC Genomics, 2016. **17**: p. 93.
- 464 9. Floriano, B., E. Santero, and F. Reyes-Ramírez, *Biodegradation of Tetralin: Genomics, Gene*
465 *Function and Regulation*. Genes (Basel), 2019. **10**(5).
- 466 10. Romine, M.F., et al., *Complete sequence of a 184-kilobase catabolic plasmid from*
467 *Sphingomonas aromaticivorans F199*. J Bacteriol, 1999. **181**(5): p. 1585-602.
- 468 11. Wittich, R.M., et al., *Metabolism of dibenzo-p-dioxin by Sphingomonas sp. strain RW1*. Appl
469 Environ Microbiol, 1992. **58**(3): p. 1005-10.
- 470 12. Copley, S.D., et al., *The whole genome sequence of Sphingobium chlorophenolicum L-1:*
471 *insights into the evolution of the pentachlorophenol degradation pathway*. Genome Biol Evol,
472 2012. **4**(2): p. 184-98.
- 473 13. Aulestia, M., et al., *Isolation and genomic characterization of the ibuprofen-degrading*
474 *bacterium Sphingomonas strain MPO218*. Environ Microbiol, 2021. **23**(1): p. 267-280.
- 475 14. Ohtsubo, Y., et al., *Complete Genome Sequence of Sphingopyxis macrogoltabida Type Strain*
476 *NBRC 15033, Originally Isolated as a Polyethylene Glycol Degradator*. Genome Announc, 2015.
477 **3**(6).
- 478 15. Yamatsu, A., et al., *Isolation and characterization of a novel poly(vinyl alcohol)-degrading*
479 *bacterium, Sphingopyxis sp. PVA3*. Appl Microbiol Biotechnol, 2006. **72**(4): p. 804-11.
- 480 16. Kawai, F., *Sphingomonads involved in the biodegradation of xenobiotic polymers*. J Ind
481 Microbiol Biotechnol, 1999. **23**(4-5): p. 400-407.
- 482 17. Masai, E., et al., *Genetic and biochemical characterization of a 2-pyrone-4, 6-dicarboxylic acid*
483 *hydrolase involved in the protocatechuate 4, 5-cleavage pathway of Sphingomonas*
484 *paucimobilis SYK-6*. J Bacteriol, 1999. **181**(1): p. 55-62.
- 485 18. García-Romero, I., et al., *SuhB, a small non-coding RNA involved in catabolite repression of*
486 *tetralin degradation genes in Sphingopyxis granuli strain TFA*. Environ Microbiol, 2018.
487 **20**(10): p. 3671-3683.
- 488 19. Zhu, L., et al., *Cloning and characterization of genes involved in nostoxanthin biosynthesis of*
489 *Sphingomonas elodea ATCC 31461*. PLoS One, 2012. **7**(4): p. e35099.
- 490 20. Li, A., et al., *A Carotenoid- and Poly-β-Hydroxybutyrate-Free Mutant Strain of*. mSphere,
491 2019. **4**(5).
- 492 21. Kontur, W.S., et al., *Novosphingobium aromaticivorans uses a Nu-class glutathione S -*
493 *transferase as a glutathione lyase in breaking the β-aryl ether bond of lignin*. J Biol Chem,
494 2018. **293**(14): p. 4955-4968.
- 495 22. Cai, C., et al., *Developing Rhodococcus opacus and Sphingobium sp. coculture systems for*
496 *valorization of lignin-derived dimers*. Biotechnol Bioeng, 2022. **119**(11): p. 3162-3177.
- 497 23. Basta, T., et al., *Detection and characterization of conjugative degradative plasmids in*
498 *xenobiotic-degrading Sphingomonas strains*. J Bacteriol, 2004. **186**(12): p. 3862-72.
- 499 24. Kaczmarczyk, A., J.A. Vorholt, and A. Francez-Charlot, *Markerless gene deletion system for*
500 *sphingomonads*. Appl Environ Microbiol, 2012. **78**(10): p. 3774-7.
- 501 25. Song, D., et al., *The variations of native plasmids greatly affect the cell surface hydrophobicity*
502 *of sphingomonads*. mSystems, 2023: p. e0086223.

- 503 26. Lu, H. and Y. Huang, *Transcriptome Analysis of Novosphingobium pentaromativorans US6-1*
504 *Reveals the Rsh Regulon and Potential Molecular Mechanisms of N -acyl-L-homoserine*
505 *Lactone Accumulation*. Int J Mol Sci, 2018. **19**(9).
- 506 27. Cecil, J.H., et al., *Rapid, Parallel Identification of Catabolism Pathways of Lignin-Derived*
507 *Aromatic Compounds in Novosphingobium aromaticivorans*. Appl Environ Microbiol, 2018.
508 **84**(22).
- 509 28. Gottschlich, L., et al., *Complex general stress response regulation in Sphingomonas melonis*
510 *Fr1 revealed by transcriptional analyses*. Sci Rep, 2019. **9**(1): p. 9404.
- 511 29. Fujita, M., et al., *Iron acquisition system of Sphingobium sp. strain SYK-6, a degrader of lignin-*
512 *derived aromatic compounds*. Sci Rep, 2020. **10**(1): p. 12177.
- 513 30. Yu, Z., et al., *The LuxI/LuxR-Type Quorum Sensing System Regulates Degradation of Polycyclic*
514 *Aromatic Hydrocarbons via Two Mechanisms*. Int J Mol Sci, 2020. **21**(15).
- 515 31. Higuchi, Y., et al., *Roles of two glutathione S-transferases in the final step of the β -aryl ether*
516 *cleavage pathway in Sphingobium sp. strain SYK-6*. Sci Rep, 2020. **10**(1): p. 20614.
- 517 32. Liang, J., et al., *Benzo[a]pyrene might be transported by a TonB-dependent transporter in*
518 *Novosphingobium pentaromativorans US6-1*. J Hazard Mater, 2021. **404**(Pt A): p. 124037.
- 519 33. Presley, G.N., et al., *Pathway discovery and engineering for cleavage of a β -1 lignin-derived*
520 *biaryl compound*. Metab Eng, 2021. **65**: p. 1-10.
- 521 34. Huang, J., et al., *Coinducible Catabolism of 1-Naphthol via Synergistic Regulation of the Initial*
522 *Hydroxylase Genes in Sphingobium sp. Strain B2*. Appl Environ Microbiol, 2021. **87**(11).
- 523 35. Gao, C., et al., *Bisphenol A biodegradation by Sphingomonas sp. YK5 is regulated by acyl-*
524 *homoserine lactone signaling molecules*. Sci Total Environ, 2022. **802**: p. 149898.
- 525 36. Fujita, M., et al., *Functional roles of multiple Ton complex genes in a Sphingobium degrader*
526 *of lignin-derived aromatic compounds*. Sci Rep, 2021. **11**(1): p. 22444.
- 527 37. Linz, A.M., et al., *Aromatic Dimer Dehydrogenases from Novosphingobium aromaticivorans*
528 *Reduce Monoaromatic Diketones*. Appl Environ Microbiol, 2021. **87**(24): p. e0174221.
- 529 38. Higuchi, Y., et al., *The Catabolic System of Acetovanillone and Acetosyringone in Sphingobium*
530 *sp. Strain SYK-6 Useful for Upgrading Aromatic Compounds Obtained through Chemical*
531 *Lignin Depolymerization*. Appl Environ Microbiol, 2022. **88**(16): p. e0072422.
- 532 39. Wang, Z., et al., *The quorum sensing system of Novosphingobium sp. ERN07 regulates*
533 *aggregate formation that promotes cyanobacterial growth*. Sci Total Environ, 2022. **851**(Pt
534 2): p. 158354.
- 535 40. Jiang, W., et al., *Comparative Genomic Analysis of Carbofuran-Degrading Sphingomonads*
536 *Reveals the Carbofuran Catabolism Mechanism in Sphingobium sp. Strain CFD-1*. Appl
537 Environ Microbiol, 2022. **88**(22): p. e0102422.
- 538 41. Martínez-García, E. and V. de Lorenzo, *Engineering multiple genomic deletions in Gram-*
539 *negative bacteria: analysis of the multi-resistant antibiotic profile of Pseudomonas putida*
540 *KT2440*. Environ Microbiol, 2011. **13**(10): p. 2702-16.
- 541 42. Wirth, N.T., E. Kozaeva, and P.I. Nikel, *Accelerated genome engineering of Pseudomonas*
542 *putida by I-SceI-mediated recombination and CRISPR-Cas9 counterselection*. Microb
543 Biotechnol, 2020. **13**(1): p. 233-249.
- 544 43. Leal-Morales, A., et al., *Transcriptional organization and regulation of the Pseudomonas*
545 *putida flagellar system*. Environ Microbiol, 2022. **24**(1): p. 137-157.
- 546 44. de Dios, R., E. Santero, and F. Reyes-Ramírez, *The functional differences between paralogous*
547 *regulators define the control of the general stress response in Sphingopyxis granuli TFA*.
548 Environ Microbiol, 2022. **24**(4): p. 1918-1931.
- 549 45. Kohlstedt, M., et al., *Biobased PET from lignin using an engineered cis, cis-muconate-*
550 *producing Pseudomonas putida strain with superior robustness, energy and redox properties*.
551 Metab Eng, 2022. **72**: p. 337-352.
- 552 46. Owen, S.V., et al., *Prophages encode phage-defense systems with cognate self-immunity*. Cell
553 Host Microbe, 2021. **29**(11): p. 1620-1633.e8.

- 554 47. Nies, S.C., et al., *High titer methyl ketone production with tailored Pseudomonas taiwanensis*
555 *VLB120*. *Metab Eng*, 2020. **62**: p. 84-94.
- 556 48. Hobmeier, K., et al., *Anaplerotic Pathways in Halomonas elongata: The Role of the Sodium*
557 *Gradient*. *Front Microbiol*, 2020. **11**: p. 561800.
- 558 49. de Dios, R., K. Gadar, and R.R. McCarthy, *A high-efficiency scar-free genome-editing toolkit*
559 *for Acinetobacter baumannii*. *J Antimicrob Chemother*, 2022. **77**(12): p. 3390-3398.
- 560 50. de Dios, R., et al., *Two paralogous EcfG σ factors hierarchically orchestrate the activation of*
561 *the General Stress Response in Sphingopyxis granuli TFA*. *Sci Rep*, 2020. **10**(1): p. 5177.
- 562 51. González-Flores, Y.E., et al., *The response of Sphingopyxis granuli strain TFA to the hostile*
563 *anoxic condition*. *Scientific Reports*, 2019. **9**(1): p. 6297.
- 564 52. Kast, P., *pKSS—a second-generation general purpose cloning vector for efficient positive*
565 *selection of recombinant clones*. *Gene*, 1994. **138**(1-2): p. 109-14.
- 566 53. Trebosc, V., et al., *A Novel Genome-Editing Platform for Drug-Resistant Acinetobacter*
567 *baumannii Reveals an AdeR-Unrelated Tigecycline Resistance Mechanism*. *Antimicrob Agents*
568 *Chemother*, 2016. **60**(12): p. 7263-7271.
- 569 54. Martínez-García, E., et al., *SEVA 4.0: an update of the Standard European Vector Architecture*
570 *database for advanced analysis and programming of bacterial phenotypes*. *Nucleic Acids*
571 *Res*, 2023. **51**(D1): p. D1558-D1567.
- 572

We would like to thank the reviewers for their constructive feedback, we believe it has helped to improve the quality of this manuscript. Please find below a point-by-point response to the comments.

Reviewer 1

The manuscript entitled "An improved genome editing system for Sphingomonadaceae" describes a detailed protocol for the construction of deletion mutants. The protocol has been optimized for *Sphingopyxis granuli* and validated by constructing a deletion mutant in the *ecfG2* gene.

In general, the manuscript is well organized, and demonstrates that the improved protocol is superior to previous and similar methodologies. More important, it can be used in other bacteria recalcitrant to genetic manipulation, if they are naturally resistant to streptomycin.

Nevertheless, I have some suggestions that could improve the manuscript.

1. This is a methodological work, and the results are the improved protocol. Therefore, instead of calling "Methods" the section found in line 124, I suggest calling it "Results".

We appreciate this suggestion, and we agree that, as a Methods manuscript, the result is the method itself. However, we also think that the methodological explanation offered does not qualify as just results. Considering this suggestion, we have corrected "Methods" to "Protocol optimisation: methods and results" in an attempt to merge both concepts.

2. There is not "Discussion" section. It would be advisable to introduce a short discussion comparing the improved protocol to previous ones, giving some conclusions, and highlighting the possible applicability of the methodology to other bacteria.

Thank you very much for this suggestion. We have now included a brief Discussion section explaining the advantages of this strategy with respect to other previous approaches and introducing specific parts of the procedure that are amenable to adaptation if using sphingomonad species different to our *S. granuli* model.

Reviewer 2

This report describes a modification of the *Scel*-based genome editing method that is currently used in *Pseudomonas*, to be used in Sphingomonadaceae. The clever approach of the authors, includes the forcing of a second recombination in a different mating process from that what incorporates in the target strain the plasmid containing the *Scel* sites. This smart technique has been possible due to the vast knowledge that the authors have accumulated about *Sphingomonas granuli* strain TFA as can be deduced from their publications, and kindly applied here.

However, some minor comments will improve the final quality of the paper.

A short phrase would be included to emphasize that the deletion of *ecfG2* is not deleterious, and that the mutant bacteria behaves similarly to wt strain.

Thank you for this comment, we have now included a sentence explaining this.

L237-238: "Although *ecfG2* is essential under stressing conditions, a mutant in this gene shows a similar fitness compared to the wild type TFA in the absence of stress".

Line 67. In this regard, delete s

Thank you for this comment, the text has been corrected accordingly.

Line 182. Rephrase... drastically reduces the number of clones reduces the number of

Thank you for this comment, the text has been corrected accordingly.

Line 349. Rephrase ...clones after obtained...

Thank you for this comment, the text has been corrected accordingly.

Throughout the text: To be smarter avoid colloquial use of techniques. Plasmids are not transformed into strains. Strains are transformed with plasmids. Examples: Lines 344, 363 and others. Please revise the whole text.

Thank you for this suggestion, we have corrected this throughout the text and in the supplementary material.